Celltrion Confirms Efficacy of COVID-19 Antibody Treatment in Phase 3 Clinical Trial

[Asia Economy Reporter Minwoo Lee] Celltrion announced on the 14th that the Phase 3 clinical trial results of its COVID-19 antibody treatment (CT-P59), 'Rekkirona', showed a 70% reduction in the incidence of severe cases or death among 1,315 trial subjects (880 high-risk subjects), with a 72% reduction in the high-risk group.

The company explained, "The number of patients who experienced one or more adverse reactions after administration of the investigational drug was similar between the CT-P59 treatment group and the placebo group," adding, "Overall, no safety concerns were observed in the CT-P59 treatment group, demonstrating its safety."

Celltrion is currently pursuing overseas approvals, including in Europe, based on the Phase 2 clinical trial report, and plans to continuously seek overseas approvals, including in Europe and the United States, based on the Phase 3 clinical trial results. Additionally, the company stated that it will submit a formal product approval application to the Ministry of Food and Drug Safety (MFDS) for Rekkirona, which has received conditional approval in Korea.

This content was produced with the assistance of AI translation services.